CD117 expression in diffuse large B-cell lymphomas: Fact or fiction?

Pathology International

Volumn 55, Issue 11, 2005, Pages 716-723

  Vakiani, Efsevia ^a   Cattoretti, Giorgio ^a   Colovai, Adriana I ^a   Murty, Vundavalli V ^a   Alobeid, Bachir ^a   Bhagat, Govind ^a  

^a Columbia University ^*  (United States)

Author keywords

CD117; EBV; Immunohistochemistry; KIT; Lymphoma; Microarray; Plasmablastic lymphoma

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BONE MARROW; CASE REPORT; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHADENOPATHY; MALE; NASOPHARYNX TUMOR; ONCOGENE; PHENOTYPE; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; STOMACH TUMOR; TISSUE MICROARRAY; TUMOR BIOPSY;

BONE NEOPLASMS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; SPLENIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 28444470851     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01893.x     Document Type: Article

References (54)

1. Horie K, Fujita J, Takakura K et al. The expression of c-kit protein in human adult and fetal tissues. Hum Reprod 1993; 8: 1955-62.
2. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998; 30: 459-66.
3. Ishikawa K, Komuro T, Hirota S, Kitamura Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: A comparison of control and Ws/Ws mutant rats. Cell Tissue Res 1997; 289: 137-43.
4. Austen KF, Boyce JA. Mast cell lineage development and phenotypic notypic regulation. Leuk Res 2001; 25: 511-18.
5. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347-9.
6. Lyman SD, Jacobsen SE. c-kit ligand and FIt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-34.
7. Loveland KL, Schlatt S. Stem cell factor and c-kit in the mammalian testis: Lessons originating from Mother Nature's gene knockouts. J Endocrinol 1997; 153: 337-44.
8. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 2003; 16: 287-96.
9. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-95.
10. Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305-13.
11. Longley BJ Jr, Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-14.
12. Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: Recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003; 10: 31-9.
13. Makhlouf HR, Remotti HE, Ishak KG. Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol 2002; 26: 493-7.
14. Sekido Y, Obata Y, Ueda R et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991; 51: 2416-19.
15. Lin ZH, Han EM, Lee ES et al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol 2004; 17: 611-16.
16. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: An ancillary marker for adenoid cystic carcinoma. Mod Pathol 2003; 16: 1224-31.
17. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: Implications for a new therapeutic approach. Mod Pathol 2003; 16: 1035-40.
18. Chui X, Egami H, Yamashita J et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73: 1233-6.
19. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: A comparative immunohistochemical study. Am J Surg Pathol 2002; 26: 486-92.
20. Chen J, Yanuck RR III, Abbondanzo SL, Chu WS, Aguilera NS. c-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma. Arch Pathol Lab Med 2001; 125: 1448-52.
21. Natkunam Y, Rouse RV. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Am J Surg Pathol 2000; 24: 81-91.
22. Sykora KW, Tomeczkowski J, Reiter A. C-kit receptors in childhood malignant lymphoblastic cells. Leuk Lymphoma 1997; 25: 201-16.
23. Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 1996; 95: 489-93.
24. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood 1994; 83: 785-92.
25. Aldinucci D, Poletto D, Nanni P et al. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002; 118: 1055-64.
26. Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2004; 17: 946-53.
27. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001; 171-4.
28. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
29. Schlegelberger B. Cytogenetic subtyping of diffuse large B-cell lymphomas. Ann Hematol 2001; 80 (Suppl. 3): B32-34.
30. de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509-28.
31. Shaknovich R, Celestine A, Yang L, Cattoretti G. Novel relational database for tissue microarray analysis. Arch Pathol Lab Med 2003; 127: 492-4.
32. Takeda S, Shimizu T, Rodewald HR. Interactions between c-kit and stem cell factor are not required for B-cell development in vivo. Blood 1997; 89: 518-25.
33. Nakatsuka S, Hongyo T, Syaifudin M, Nomura T, Shingu N, Aozasa K. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland. Jpn J Cancer Res 2002; 93: 267-74.
34. Brown RE, Nazmi RK. The Reed-Steinberg cell: Molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 2002; 32: 339-51.
35. Rassidakis GZ, Georgakis GV, Younes A, Medeiros LJ. c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Blood 2003; 102: 4619-20.
36. Yantiss RK, Spiro IJ, Compton CC, Rosenberg AE. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: A clinically important differential diagnosis. Am J Surg Pathol 2000; 24: 947-57.
37. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-93.
38. Miettinen M. Are desmoid tumors kit positive? Am J Surg Pathol 2001; 25: 549-50.
39. Lucas DR, al-Abbadi M, Tabaczka P, Hamre MR, Weaver DW, Mott MJ. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003; 119: 339-45.
40. Bravo P, Agustin BD, Bellas C et al. Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. Am J Hematol 2000; 63: 226-9.
41. Potti A, Ganti AK, Kargas S, Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002; 22: 2899-901.
42. Tomeczkowski J, Beilken A, Frick D et al. Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt's lymphoma cells. Blood 1995; 86: 1469-80.
43. Zimpfer A, Went P, Tzankov A et al. Rare expression of KIT (CD117) in lymphomas: A tissue microarray study of 1166 cases. Histopathology 2004; 45: 398-404.
44. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
45. Delecluse HJ, Anagnostopoulos I, Dallenbach F et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997; 89: 1413-20.
46. Klein U, Gloghini A, Gaidano G et al. Gene expression profile analysis of AlDS-related primary effusion lymphoma(PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003; 101: 4115-21.
47. Colomo L, Loong F, Rives S et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28: 736-47.
48. Gascoyne RD, Lamant L, Martin-Subero JI et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: Report of 6 cases. Blood 2003; 102: 2568-73.
49. Du MQ, Diss TC, Liu H et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100: 3415-18.
50. Vega F, Chang CC, Medeiros LJ et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2004; 18: 806-15.
51. Bayer-Garner IB, Schwartz MR, Lin P, Smoller BR. CD117, but not lysozyme, is positive in cutaneous plasmacytoma. Arch Pathol Lab Med 2003; 127: 1596-8.
52. Kraj M, Poglod R, Kopec-Szlezak J, Sokolowska U, Wozniak J, Kruk B. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004; 45: 2281-9.
53. Lemoli RM, Fortuna A, Grande A et al. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. Br J Haematol 1994; 88: 760-69.
54. Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 2004; 444: 264-8.